SCHEMBL25263244

SCHEMBL25263244

Cc1c(Br)nc2ccc(Cl)cn12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
GAA P10253 5/20 0.44
POLB P06746 3/20 0.44
PIK3CD O00329 1/20 0.42
PIK3R1 P27986 1/20 0.42
MAP3K14 Q99558 1/20 0.42
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 5/20 0.38
KDM4E B2RXH2 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
AHR P35869 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13036621 0.81 ALDH1A1 (0.54) ALDH1A1GAAPOLBPIK3CDPIK3R1
SCHEMBL9924061 0.78 PIK3CD (0.49) ALDH1A1GAAPOLBPIK3CDPIK3R1
SCHEMBL18894160 0.78 ALDH1A1 (0.51) ALDH1A1GAAPOLBPIK3CDPIK3R1
Hydrochloric Acid SCHEMBL9893311 0.76 PIK3CD (0.48) ALDH1A1GAAPOLBPIK3CDPIK3R1
SCHEMBL6101637 0.76 ALDH1A1 (0.47) ALDH1A1GAAPOLBPIK3CDPIK3R1
SCHEMBL16160310 0.75 GAA (0.42) ALDH1A1GAAPOLBPIK3CDPIK3R1
SCHEMBL23655363 0.75 ALDH1A1 (0.46) ALDH1A1GAAPOLBPIK3CDPIK3R1
SCHEMBL16462376 0.74 GAA (0.44) ALDH1A1GAAPOLBPIK3CDPIK3R1
SCHEMBL16462653 0.74 ALDH1A1 (0.48) ALDH1A1GAAPOLBPIK3CDPIK3R1
SCHEMBL22591242 0.74 TRPA1 (0.44) ALDH1A1POLBRAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099442-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES INC 2025-03-27 US disclosed
EP-4444721-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2024-10-16 EP disclosed
WO-2023107722-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099442-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS DYRK2, DYRK1A, DYRK1B ALDH1A1 2359/4885GAA 245/4885POLB 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.